The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
The Association of Chemotherapy-Induced Peripheral Neuropathy Symptoms and the Risk of Falling
Open accessAbstract
IMPORTANCE: Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect of neurotoxic chemotherapy resulting in pain, sensory loss, and decreased quality of life. Few studies have prospectively examined the relationship between sensory neuropathy symptoms, falls, and fall-related injuries for patients receiving neurotoxic chemotherapy. OBJECTIVE: To determine the association between the symptoms of CIPN and the risk of falls for patients receiving neurotoxic chemotherapy. DESIGN, SETTING, AND PARTICIPANTS: In this secondary analysis of a prospective study, 116 patients with breast, ovarian, or lung cancer who were beginning neurotoxic chemotherapy with a taxane or platinum agent were recruited from oncology clinics. These patients would call a novel automated telephone system daily for 1 full course of chemotherapy. The telephone system (SymptomCare@Home) used a series of relevant CIPN questions to track symptoms on a 0 to 10 ordinal scale and contained a questionnaire about falls. Those reporting a numbness and tingling severity score of 3 or greater for at least 10 days were considered to have significant CIPN symptoms and were compared with those patients who did not. Data analysis was performed in November 2015. EXPOSURE: Chemotherapy with a neurotoxic taxane or platinum agent. MAIN OUTCOMES AND MEASURES: Patient-reported falls or near falls and fall-related injuries. The hypothesis was generated after data collection but prior to data analysis. RESULTS: Of the 116 patients who started neurotoxic chemotherapy (mean [SD] age was 55.5 [11.9] years, and 109 [94.0%] were female), 32 met the predetermined criteria for CIPN symptoms. The mean duration of follow-up was 62 days, with 51 telephone calls completed per participant. Seventy-four falls or near falls were reported. The participants with CIPN symptoms were nearly 3 times more likely to report a fall or near fall than the participants without CIPN symptoms (hazard ratio, 2.67 [95% CI, 1.62-4.41]; P < .001). The participants with CIPN symptoms were more likely than the participants without CIPN symptoms to obtain medical care for falls (8 of 32 participants with CIPN symptoms [25.0%] vs 6 of 84 participants without CIPN symptoms [7.1%]; P = .01). CONCLUSIONS AND RELEVANCE: These findings suggest that the sensory symptoms of CIPN are an indicator of an increased risk of falling and an increased use of health care resources. This study demonstrates the utility of a novel telephone-based system to track neuropathy symptoms. Careful monitoring and coaching of patients receiving neurotoxic chemotherapy for new sensory symptoms may facilitate more effective fall prevention strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Modeling and variable selection in epidemiologic analysis
Greenland, S. (1989) · American Journal of Public Health · doi:10.2105/ajph.79.3.340 · Cited by 2,208
The epidemiology of falls and syncope
Rubenstein, L. Z., & Josephson, K. R. (2002) · Clinics in Geriatric Medicine · doi:10.1016/s0749-0690(02)00002-2 · Cited by 1,176
Chemotherapy-induced peripheral neuropathy
Quasthoff, S., & Hartung, H. P. (2002) · Journal of Neurology · doi:10.1007/pl00007853 · Cited by 966
Fear of falling and restriction of mobility in elderly fallers
VELLAS, B. J., WAYNE, S. J., ROMERO, L. J., BAUMGARTNER, R. N., & GARRY, P. J. (1997) · Age and Ageing · doi:10.1093/ageing/26.3.189 · Cited by 899
Ganz, D. A., Bao, Y., Shekelle, P. G., & Rubenstein, L. Z. (2007) · JAMA · doi:10.1001/jama.297.1.77 · Cited by 818
Oxaliplatin: A review of preclinical and clinical studies
Raymond, E., Chaney, S. G., Taamma, A., & Cvitkovic, E. (1998) · Annals of Oncology · doi:10.1023/a:1008213732429 · Cited by 643
Chemotherapy‐induced neuropathy
Windebank, A. J., & Grisold, W. (2008) · Journal of the Peripheral Nervous System · doi:10.1111/j.1529-8027.2008.00156.x · Cited by 613
Chemotherapy-induced peripheral neurotoxicity (CIPN): An update
Argyriou, A. A., Bruna, J., Marmiroli, P., & Cavaletti, G. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.04.012 · Cited by 568
El-Khoury, F., Cassou, B., Charles, M.-A., & Dargent-Molina, P. (2015) · British Journal of Sports Medicine · doi:10.1136/bmj.f6234 · Cited by 425
Mols, F., Beijers, T., Lemmens, V., van den Hurk, C. J., Vreugdenhil, G., & van de Poll-Franse, L. V. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.1514 · Cited by 359
Cited by
Mechanisms of Chemotherapy-Induced Peripheral Neuropathy
Zajączkowska, R., Kocot-Kępska, M., Leppert, W., Wrzosek, A., Mika, J., & Wordliczek, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061451 · Cited by 829
Winters-Stone, K. M., Horak, F., Jacobs, P. G., Trubowitz, P., Dieckmann, N. F., Stoyles, S., & Faithfull, S. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.3552 · Cited by 368
Metadata
- Authors
- Kolb, N. A., Smith, A. G., Singleton, J. R., Beck, S. L., Stoddard, G. J., Brown, S., & Mooney, K.
- Venue
- JAMA Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2016-07-01
- Volume
- 73
- Issue
- 7
- Pages
- 860
- ISSN
- 2168-6149 (ISSN-L)
- OpenAlex
- W2359816812
- Cited by
- 276
- References
- 30
- FWCI
- 9.27
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Association of Chemotherapy-Induced Peripheral Neuropathy Symptoms and the Risk of Falling. https://app.cochat.ai/papers/10.1001/jamaneurol.2016.0383
- The paper
- Kolb, N. A., Smith, A. G., Singleton, J. R., Beck, S. L., Stoddard, G. J., Brown, S., & Mooney, K. (2016). The Association of Chemotherapy-Induced Peripheral Neuropathy Symptoms and the Risk of Falling. JAMA Neurology. https://doi.org/10.1001/jamaneurol.2016.0383
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.